Moreover, the multicenter phase III PROFILE 1007 trial compared crizotinib with either pemetrexed or docetaxel in the second-line setting in patients with locally advanced or metastatic ALK-positive NSCLC after disease progression on one prior platinum-based regimen. This evidence concerns the gene ALK and non-small cell lung carcinoma.